Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer

Journal of Urology

Volumn 181, Issue 6, 2009, Pages 2520-2525

  Park, Yong Hyun ^a   Hwang, In Sik ^a   Jeong, Chang Wook ^a   Kim, Hyeon Hoe ^a   Lee, Sang Eun ^a   Kwak, Cheol ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

drug therapy; prostate specific antigen; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER SURVIVAL; GLEASON SCORE; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; CASTRATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 67349131277     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.01.104     Document Type: Article

References (20)

1. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
2. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
3. Smaletz O., Scher H.I., Small E.J., Verbel D.A., McMillan A., Regan K., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972
4. Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232
5. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22 (1972) 232
6. Arai Y., Yoshiki T., and Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 144 (1990) 1415
7. Cooper E.H., Armitage T.G., Robinson M.R., Newling D.W., Richards B.R., Smith P.H., et al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 66 (1990) 1025
8. Aihara M., Lebovitz R.M., Wheeler T.M., Kinner B.M., Ohori M., and Scardino P.T. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol 151 (1994) 1558
9. Berruti A., Mosca A., Tucci M., Terrone C., Torta M., Tarabuzzi R., et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 12 (2005) 109
10. Coffey R.N., Watson R.W., O'Neill A.J., Mc Eleny K., and Fitzpatrick J.M. Androgen-mediated resistance to apoptosis. Prostate 53 (2002) 300
11. Shinomiya N. New concepts in radiation-induced apoptosis: 'premitotic apoptosis' and 'postmitotic apoptosis'. J Cell Mol Med 5 (2001) 240
12. Kestin L.L., Vicini F.A., Ziaja E.L., Stromberg J.S., Frazier R.C., and Martinez A.A. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 86 (1999) 1557
13. Ray M.E., Thames H.D., Levy L.B., Horwitz E.M., Kupelian P.A., Martinez A.A., et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 64 (2006) 1140
14. Lee W.R., Hanlon A.L., and Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol 156 (1996) 450
15. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297
16. Pollack A., Zagars G.K., Starkschall G., Antolak J.A., Lee J.J., Huang E., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097
17. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
18. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet 346 (1995) 265
19. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355 (2000) 1491
20. Samson D.J., Seidenfeld J., Schmitt B., Hasselblad V., Albertsen P.C., Bennett C.L., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 (2002) 361